RxDoctor Payments Data

Lauren Lumley, DO

Family Medicine · Plymouth, MINPI 1356916076

Payments from drug & device makers

$2,316in general payments, 2019–2025

Across 25 payments — averaging $92.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$531
  • Sanofi$496
  • GSK$445
  • Johnson & Johnson$252
  • Takeda Pharmaceuticals U.S.A., Inc.$247
  • CSL Behring$125
  • plus $219 from 5 others

What the payments were for

  • Food & beverage$2,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,316 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$11,918
Medicare patients
64
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$39,978
JardianceEmpagliflozin31$35,691
EliquisApixaban15$20,509
MounjaroTirzepatide14$14,395
XareltoRivaroxaban15$7,976
Varenicline Tartrate13$4,679
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,011
Atorvastatin Calcium83$1,167
Albuterol Sulfate HfaAlbuterol Sulfate25$994
Diclofenac Sodium14$830
Omeprazole42$782
Duloxetine Hcl38$763
Olmesartan Medoxomil15$730
Rosuvastatin Calcium63$667
Levothyroxine Sodium47$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$531$39,97829 claims
Lilly USA, LLCMounjaro$20$14,39514 claims
Johnson & JohnsonXarelto$252$7,97615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Plymouth

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →